Last reviewed · How we verify
NCT00827580
A Pilot Study of Eniluracil Containing Ointment for Prevention of Hand Foot Syndrome (HRS) Following Capecitabine (Xeloda)
Phase 1 trial testing Eniluracil in Breast Cancer in 3 participants. Terminated before completion.
1 September 2009
Quick facts
| Lead sponsor | West Virginia University |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 1 January 2009 |
| Primary completion | 1 September 2009 |
| Estimated completion | 1 September 2009 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Eniluracil — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Colon Cancer — all drugs for Colon Cancer →
Sponsor
West Virginia University
Who can join
18 and older, any sex, with Breast Cancer or Colon Cancer. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
- the frequency of HFS; evaluation of eniluracil dose response; and assessment of any toxicity related to the topical product.
Sponsor's own description
A pilot study of eniluracil containing ointment for prevention of hand foot syndrome (HRS) following capecitabine (Xeloda).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00827580
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other West Virginia University trials
Trials by the same sponsor.
- NCT06686914 — The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex · Phase 1 · recruiting
- NCT06791850 — Sustaining Home Heart Failure Palliative Care in Rural Appalachia · NA · recruiting
- NCT05705999 — Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study · NA · recruiting
- NCT05353244 — Effects of PrTMS on Performance · NA · withdrawn
- NCT06612788 — Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00827580 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by West Virginia University
- Last refreshed: 25 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00827580.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing